Trial reportCancer science2021
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Trial report in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03950674 (A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab), which is not on this map. Cited by 43 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)
Who cites it
43 citing papers in PubMed, 12 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes.The clinical respiratory journal · 2026Pooled it
- Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.The Indian journal of medical research · 2026Pooled it
- Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs.BMC cancer · 2025Pooled it
- First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.Frontiers in oncology · 2025Pooled it
- The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.Frontiers in oncology · 2025Pooled it
- East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis.Cancer medicine · 2024Pooled it
- Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.Cancer medicine · 2023Pooled it
- Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Pooled it
- Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.International journal of clinical oncology · 2023Trial
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.International journal of clinical oncology · 2022Trial
- Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer science · 2021Trial
- Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671.JTO clinical and research reports · 2026Article
- Increased Lymphocyte Proportions as a Candidate Biomarker for Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy.Cancer medicine · 2026Article
- Long-Term Survival Heterogeneity Across PD-L1-Defined Subgroups in Pembrolizumab-Treated Non-Small-Cell Lung Cancer: A Model-Based Analysis.Pharmaceutics · 2026Article
- Cemiplimab in Japanese patients with advanced non-small cell lung cancer.Japanese journal of clinical oncology · 2026Article
- A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC.JTO clinical and research reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 2 countries.
Funding
Abstract
Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety compared with placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study. We present results of Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies. Patients were randomized 2:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks (Q3W) for up to 35 cycles. All patients received pemetrexed 500 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.